imiquimod has been researched along with ascorbic acid in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Fabi, SG; Zaleski-Larsen, LA | 1 |
| Hara, Y; Kawada, A; Kitahata, K; Matsuo, K; Naganuma, T; Nakayama, T; Oiso, N | 1 |
| Bailie, JE; Burke, B | 1 |
1 review(s) available for imiquimod and ascorbic acid
| Article | Year |
|---|---|
Laser-Assisted Drug Delivery.
Topics: Administration, Cutaneous; Adrenergic beta-Antagonists; Aminolevulinic Acid; Aminoquinolines; Analgesics; Antibodies; Antineoplastic Agents; Ascorbic Acid; Cyclopropanes; Dermatologic Agents; Drug Delivery Systems; Fluorouracil; Humans; Imiquimod; Immunotherapy; Laser Therapy; Methotrexate; Minoxidil; Permeability; Photosensitizing Agents; Polyesters; RNA, Small Interfering; Skin; Timolol; Vaccines | 2016 |
1 trial(s) available for imiquimod and ascorbic acid
| Article | Year |
|---|---|
Randomized trial of topical ascorbic acid in DMSO versus imiquimod for the treatment of basal cell carcinoma.
Topics: Administration, Topical; Aminoquinolines; Antineoplastic Agents; Ascorbic Acid; Carcinoma, Basal Cell; Dimethyl Sulfoxide; Humans; Imiquimod; Skin Neoplasms; Treatment Outcome | 2022 |
1 other study(ies) available for imiquimod and ascorbic acid
| Article | Year |
|---|---|
Ascorbic acid derivative DDH-1 ameliorates psoriasis-like skin lesions in mice by suppressing inflammatory cytokine expression.
Topics: Animals; Anti-Inflammatory Agents; Ascorbic Acid; Cytokines; Female; Imiquimod; Mice, Inbred C57BL; Psoriasis; Skin | 2018 |